|
[1]
|
Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease
Life,
2023
DOI:10.3390/life13030599
|
|
|
|
|
[2]
|
Orphan Lung Diseases
2023
DOI:10.1007/978-3-031-12950-6_13
|
|
|
|
|
[3]
|
Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
RMD Open,
2023
DOI:10.1136/rmdopen-2023-003487
|
|
|
|
|
[4]
|
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment
Reumatología Clínica (English Edition),
2022
DOI:10.1016/j.reumae.2022.03.004
|
|
|
|
|
[5]
|
Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion
Frontiers in Medicine,
2022
DOI:10.3389/fmed.2022.937561
|
|
|
|
|
[6]
|
Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies
Expert Review of Respiratory Medicine,
2022
DOI:10.1080/17476348.2022.2089116
|
|
|
|
|
[7]
|
Aktuelles zur RA-ILD
Pneumologie,
2022
DOI:10.1055/a-1895-9360
|
|
|
|
|
[8]
|
Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento
Reumatología Clínica,
2022
DOI:10.1016/j.reuma.2022.03.005
|
|
|
|
|
[9]
|
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment
Reumatología Clínica (English Edition),
2022
DOI:10.1016/j.reumae.2022.03.004
|
|
|
|
|
[10]
|
Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
Rheumatology Science and Practice,
2022
DOI:10.47360/1995-4484-2022-1
|
|
|
|
|
[11]
|
Efficacy and Safety of Rituximab in Autoimmune Disease—Associated Interstitial Lung Disease: A Prospective Cohort Study
Journal of Clinical Medicine,
2022
DOI:10.3390/jcm11040927
|
|
|
|
|
[12]
|
The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey
Rheumatology,
2022
DOI:10.1093/rheumatology/keab552
|
|
|
|
|
[13]
|
Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review
Frontiers in Medicine,
2022
DOI:10.3389/fmed.2022.837133
|
|
|
|
|
[14]
|
Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development
Autoimmunity Reviews,
2021
DOI:10.1016/j.autrev.2020.102742
|
|
|
|
|
[15]
|
Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
Journal of Clinical Medicine,
2021
DOI:10.3390/jcm10061330
|
|
|
|
|
[16]
|
Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis
Reumatología Clínica (English Edition),
2021
DOI:10.1016/j.reumae.2020.04.010
|
|
|
|
|
[17]
|
Revisión sistemática sobre el impacto de los fármacos en la enfermedad pulmonar intersticial difusa asociada a Artritis Reumatoide
Reumatología Clínica,
2021
DOI:10.1016/j.reuma.2020.04.015
|
|
|
|
|
[18]
|
Belimumab in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: Case Report and Literature Review
Cureus,
2021
DOI:10.7759/cureus.19218
|
|
|
|
|
[19]
|
Immunmodulation bei autoimmunen interstitiellen Lungenerkrankungen
Kompass Autoimmun,
2021
DOI:10.1159/000514258
|
|
|
|
|
[20]
|
Análisis de las características clínico-analíticas de pacientes con artritis reumatoide y enfermedad pulmonar intersticial: casos y controles
Reumatología Clínica,
2021
DOI:10.1016/j.reuma.2019.06.001
|
|
|
|
|
[21]
|
Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey
Joint Bone Spine,
2021
DOI:10.1016/j.jbspin.2021.105172
|
|
|
|
|
[22]
|
Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis
Internal Medicine Journal,
2020
DOI:10.1111/imj.14306
|
|
|
|
|
[23]
|
Immunomodulation in Autoimmune Interstitial Lung Disease
Respiration,
2020
DOI:10.1159/000511200
|
|
|
|
|
[24]
|
Analysis of clinical–analytical characteristics in patients with rheumatoid arthritis and interstitial lung disease: Case–control study
Reumatología Clínica (English Edition),
2020
DOI:10.1016/j.reumae.2019.06.002
|
|
|
|
|
[25]
|
Management issues in rheumatoid arthritis-associated interstitial lung disease
Current Opinion in Rheumatology,
2020
DOI:10.1097/BOR.0000000000000703
|
|
|
|
|
[26]
|
Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis
Internal Medicine Journal,
2020
DOI:10.1111/imj.14306
|
|
|
|
|
[27]
|
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows
Journal of Clinical Medicine,
2020
DOI:10.3390/jcm9041082
|
|
|
|
|
[28]
|
Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis
Clinical Rheumatology,
2020
DOI:10.1007/s10067-020-05227-9
|
|
|
|
|
[29]
|
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease
Seminars in Arthritis and Rheumatism,
2020
DOI:10.1016/j.semarthrit.2020.08.008
|
|
|
|
|
[30]
|
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease
Tuberculosis and Respiratory Diseases,
2019
DOI:10.4046/trd.2019.0009
|
|
|
|
|
[31]
|
Thoracic Manifestations of Rheumatoid Arthritis
Clinics in Chest Medicine,
2019
DOI:10.1016/j.ccm.2019.05.003
|
|
|
|
|
[32]
|
Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)
Drugs,
2019
DOI:10.1007/s40265-019-01178-x
|
|
|
|
|
[33]
|
Pulmonary Manifestations of Systemic Diseases
2019
DOI:10.1183/2312508X.10014019
|
|
|
|
|
[34]
|
Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians
Journal of Clinical Medicine,
2019
DOI:10.3390/jcm8122038
|
|
|
|
|
[35]
|
Biologic Treatments in Interstitial Lung Diseases
Frontiers in Medicine,
2019
DOI:10.3389/fmed.2019.00041
|
|
|
|
|
[36]
|
Rituximab in connective tissue disease–associated interstitial lung disease
Clinical Rheumatology,
2019
DOI:10.1007/s10067-019-04557-7
|
|
|
|
|
[37]
|
Lung Disease in Rheumatoid Arthritis
Respiratory Medicine,
2018
DOI:10.1007/978-3-319-68888-6_9
|
|
|
|
|
[38]
|
Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review
Expert Review of Clinical Immunology,
2018
DOI:10.1080/1744666X.2018.1411190
|
|
|
|
|
[39]
|
Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis
Rheumatology and Therapy,
2017
DOI:10.1007/s40744-017-0071-5
|
|
|
|
|
[40]
|
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
RMD Open,
2017
DOI:10.1136/rmdopen-2017-000473
|
|
|
|
|
[41]
|
Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre
Rheumatology,
2017
DOI:10.1093/rheumatology/kex072
|
|
|
|
|
[42]
|
Recent advances in connective tissue disease related interstitial lung disease
Expert Review of Respiratory Medicine,
2017
DOI:10.1080/17476348.2017.1335600
|
|
|
|
|
[43]
|
Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view
The Korean Journal of Internal Medicine,
2017
DOI:10.3904/kjim.2016.212
|
|
|
|
|
[44]
|
Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease
Expert Review of Clinical Immunology,
2016
DOI:10.1586/1744666X.2016.1139454
|
|
|
|
|
[45]
|
Management of connective tissue diseases associated interstitial lung disease
Current Opinion in Rheumatology,
2016
DOI:10.1097/BOR.0000000000000270
|
|
|
|
|
[46]
|
Connective tissue disease-related interstitial lung disease
Best Practice & Research Clinical Rheumatology,
2016
DOI:10.1016/j.berh.2016.04.006
|
|
|
|
|
[47]
|
Management of Connective Tissue Disease–associated Interstitial Lung Disease
Rheumatic Disease Clinics of North America,
2015
DOI:10.1016/j.rdc.2015.01.002
|
|
|
|
|
[48]
|
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
Therapeutic Advances in Musculoskeletal Disease,
2015
DOI:10.1177/1759720X15612250
|
|
|
|
|
[49]
|
Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine,
2015
DOI:10.4137/CCRPM.S23288
|
|
|
|
|
[50]
|
Interstitial lung disease in rheumatoid arthritis: Current concepts in pathogenesis, diagnosis and therapeutics
World Journal of Rheumatology,
2015
DOI:10.5499/wjr.v5.i1.1
|
|
|
|
|
[51]
|
Pulmonary Manifestations of Rheumatic Disease
2014
DOI:10.1007/978-1-4939-0770-0_3
|
|
|
|
|
[52]
|
The safety of biologic therapies in RA-associated interstitial lung disease
Nature Reviews Rheumatology,
2014
DOI:10.1038/nrrheum.2013.197
|
|
|
|
|
[53]
|
Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis
American Journal of Respiratory and Critical Care Medicine,
2014
DOI:10.1164/rccm.201407-1258LE
|
|
|
|
|
[54]
|
Pulmonary Manifestations of Rheumatic Disease
2014
DOI:10.1007/978-1-4939-0770-0_3
|
|
|
|
|
[55]
|
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis
Expert Review of Clinical Immunology,
2013
DOI:10.1586/1744666X.2013.811173
|
|
|
|